enGene CTO granted options for 195,000 shares

enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026.

Rhea-AI Filing Summary

enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026. The options give her the right to buy these shares at an exercise price of $9.53 per share and expire on January 30, 2036.

The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company. This Form 4 reports an incentive-based equity grant, with Connolly directly holding 195,000 derivative securities following the transaction.

Insider Trade Summary

Grant/Award: 195,000 shares

Grant/Award 1 txn

Insider Connolly Joan

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	195,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 195,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the enGene (ENGN) Form 4 for Joan Connolly report?

The Form 4 reports a stock option grant to CTO Joan Connolly covering 195,000 common shares. The options were awarded on January 30, 2026, and represent an equity-based incentive tied to her ongoing service with enGene Holdings Inc.

How many enGene (ENGN) shares are covered by Joan Connollys options?

Joan Connolly received stock options on 195,000 enGene common shares. These derivative securities give her the right to purchase that number of shares if she exercises the options under the terms and vesting schedule disclosed in the Form 4 filing.

What are the exercise price and expiration date of the enGene CTO stock options?

The stock options granted to enGenes CTO have an exercise price of $9.53 per share and expire on January 30, 2036. She may purchase common shares at this price once the options vest, subject to the continued service condition.

How do Joan Connollys enGene (ENGN) stock options vest?

The option grant vests monthly in substantially equal amounts over 48 months. Vesting is conditioned on Joan Connollys continued service with enGene Holdings Inc., meaning she earns the right to exercise additional portions of the grant each month over four years.

Is the enGene (ENGN) Form 4 a stock sale or a grant for the CTO?

The Form 4 shows a stock option grant to the CTO, coded as A for acquisition, not a sale. She was awarded options with an exercise price of $9.53, and no sale of underlying common shares is reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connolly Joan

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT A8 H4R 2P1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enGene Holdings Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.53	01/30/2026		A		195,000		(1)	01/30/2036	Common Shares	195,000	$0	195,000	D

Explanation of Responses:

1. This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.

	/s/ Lee G. Giguere, as attorney-in-fact for the Reporting Person	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.